Immuntoxine

Barth, Stefan; Winkler, U.; Diehl, Volker; Engert, Andreas

doi:10.1007/s001080050118

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High dose chemotherapy and stem cell transplantation in leukemia and solide tumours [3] Cancer vaccines and specific immunotherapy [4] Antibodies as specific cancer therapy with monoclonal antibodies [5] Immunotoxins [6] Human gene therapy [7] Tyrosine kinase inhibitors [8] Detection of tumor cell dissemination by immunocytology [9] Neoangiogenesis and tumour growth [10] IA* with polyclonal ab against sTNFR [11] Transforming the TA** into immunologic therapy [12] *IA: Immuno Adsorption; **TA: Therapeutic Apheresis; sTNFR: Tumor Necrosis Factor Receptor A. A comparable mechanism is observed for the new kinase inhibitors.…”

Section: Introductionmentioning

confidence: 99%

“…In these cases new drugs and therapeutic concepts must be developed continuously which are very expansive. In the last years various new sophisticated therapeutic strategies were developed of which some are summarized in Table 1 [3][4][5][6][7][8][9][10][11][12]. All the previous cancer therapeutic strategies are not effective in all patients and they are often associated with a high rate of side effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tryptophan Depletion Bioreactor, a New Cancer Therapy

Bambauer¹

2017

CTBEB

View full text Add to dashboard Cite

The cancer therapeutic strategies known to date are not adequate for all cancer patients. Most of them are followed by a high rate of side effects and complications. The L-tryptophan depletion bioreactor is described as a possible new method of cancer therapy. L-tryptophan is an essential amino acid which has been recognized as an important cancer nutrient and its removal can lead to destruction of the tumour. Normal human cells or tumor cells cannot synthesize L-tryptophan and therefore tumor resistance is unlikely to develop. L-tryptophan is also a constituent for different bio-molecules such as Serotonin, Melatonin, and is needed for other synthesis processes in the cell growth. A column which contained TSO as a bioreactor was integrated in a plasmapheresis unit and tested it in different animals. Brest cancer and medulloblastoma showed the greatest efficacy of L-tryptophan degrading. Tryptophan side chain oxydase (TSO) is developed to treat cancer diseases successfully, and has low side effects. A combination of L-tryptophan depletion with all available cancer therapies is possible.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tryptophan Depletion Bioreactor, a New Cancer Therapy

Bambauer¹

2017

CTBEB

View full text Add to dashboard Cite

show abstract

Behandlung von malignen Lymphomen mit dem mono-klonalen anti-CD20 Antikörper Rituximab (IDEC-C2B8)

et al. 1999

View full text Add to dashboard Cite

Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia

Fitting

Blume

Haaf

et al. 2015

mAbs

View full text Add to dashboard Cite

(2015) Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia, mAbs, 7:2, 390-402, DOI: 10.1080DOI: 10. /19420862.2015 To link to this article: https://doi.org/10. 1080/19420862.2015 The current standard treatment for acute myeloid leukemia (AML) is chemotherapy based on cytarabine and daunorubicine (7 C 3), but it discriminates poorly between malignant and benign cells. Dose-limiting off-target effects and intrinsic drug resistance result in the inefficient eradication of leukemic blast cells and their survival beyond remission. This minimal residual disease is the major cause of relapse and is responsible for a 5-year survival rate of only 24%. More specific and efficient approaches are therefore required to eradicate malignant cells while leaving healthy cells unaffected. In this study, we generated scFv antibodies that bind specifically to the surface of AML blast cells and AML bone marrow biopsy specimens. We isolated the antibodies by phage display, using subtractive whole-cell panning with AML M2-derived Kasumi-1 cells. By selecting for internalizing scFv antibody fragments, we focused on potentially novel agents for intracellular drug delivery and tumor modulation. Two independent methods showed that 4 binders were internalized by Kasumi-1 cells. Furthermore, we observed the AML-selective inhibition of cell proliferation and the induction of apoptosis by a recombinant immunotoxin comprising one scFv fused to a truncated form of Pseudomonas exotoxin A (ETA'). This method may therefore be useful for the selection of novel disease-specific internalizing antibody fragments, providing a novel immunotherapeutic strategy for the treatment of AML patients.

show abstract

Immuntoxine

Cited by 3 publications

References 0 publications

Tryptophan Depletion Bioreactor, a New Cancer Therapy

Tryptophan Depletion Bioreactor, a New Cancer Therapy

Behandlung von malignen Lymphomen mit dem mono-klonalen anti-CD20 Antikörper Rituximab (IDEC-C2B8)

Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia

Contact Info

Product

Resources

About